Loading…
← CockpitCompetitor Analysis › 6127.HK JOINN Laboratories (China) Co., Ltd. Class HOpen in the cockpit ↗

JOINN Laboratories (China) Co., Ltd. Class H6127.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese contract research organization running preclinical safety and non-human-primate studies for global drug developers.

≈ China's Charles River LaboratoriesMomentum neutral 45
Mkt cap
$3.70B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$17.2M
20-day average traded
Fwd P/E
14.4×
forward earnings
ROIC−WACC
-12.4 pp
WACC 13.0%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$20.08
1D-7.6%
1W-16.1%
1M-23.6%
3M-20.9%
6M+5.7%
YTD-2.5%
1Y+2.6%
ATR %9.8%
52w lowhigh38.4% off high

What JOINN Laboratories (China) does

Chinese contract research organization running preclinical safety and non-human-primate studies for global drug developers.

Charges a fee per study run on a drug developer's behalf, such as safety and toxicology tests, so income follows how many drug programmes its clients start and how well biotech funding holds up. Its own primate colony helps secure capacity. This is the Hong Kong listing of the same company as the Shanghai-listed A-share.

In one line: China's Charles River Laboratories.

Products and services

  • Preclinical safety evaluation (GLP toxicology)
  • Non-human primate research models
  • Bioanalysis services
  • Early discovery services

Customers

  • Global & Chinese pharma/biotech companies

Where it sits in the supply chain

  • Drug development services
  • Preclinical CRO
  • Non-clinical safety/toxicology testing

What could go right

  • Global biotech R&D outsourcing growth
  • Capacity expansion for large-molecule testing

What could go wrong

  • US-China biotech geopolitical/data-security risk
  • Biotech funding cycles

Moat: narrow (scale, regulatory licence, installed base). Large GLP-certified capacity and primate colonies are hard to replicate, but competes with global CROs.

Headquarters: Beijing, China · Employees: 2,649

Named competitors

JOINN Laboratories (China) at a glance

Size JOINN Laboratories (China) (6127.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $3.70B, the 296th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$20.08 on 18 Nov 2026.

Performance Over six months the shares gained 5.7%, against +1.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 16.7% over the last twelve months (peer median +5.3%); the operating margin is -3.6% (peer median -0.7%).

Valuation It trades at 14.4× forward earnings against a peer median of 26.7× (3rd cheapest of 10).

Capital Return on invested capital runs 12.4 points below its cost of capital (13.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 20266127.HK 102Peer median 101
Six months, rebased to 100: JOINN Laboratories (China) against the median of its 20 peers (local-currency closes).

JOINN Laboratories (China) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.10BHK$1.80BHK$2.19BHK$2.63BHK$2.63B
Revenue growth—-18%-17%0%—
Gross profitHK$620MHK$328MHK$577MHK$1.09BHK$1.21B
EBITDAn/aHK$36.7MHK$236MHK$793MHK$958M
Net incomeHK$1.31BHK$323MHK$80.3MHK$439MHK$1.25B
Free cash flowHK$745MHK$408MHK$287MHK$503MHK$859M
Capital expenditureHK$526MHK$156MHK$292MHK$213MHK$320M
Total debtHK$43.4MHK$24.1MHK$64.9MHK$94.5MHK$135M

Quarterly statements and history in the cockpit →

JOINN Laboratories (China) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%TNGXRLAYABCLIRONCRSP600161IOVA66966919ELVN603392002007VIRPXERS000661EWTXADMATLX6127.HK6-month return →1-month return →
Up and to the right = strong over both horizons. JOINN Laboratories (China) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×600161002007VIRP1530XERS000661ADMA002252TLX6127.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JOINN Laboratories (China) is the large dot.

JOINN Laboratories (China) competitors and peer comparison

Head to head with its named competitors (6127.HK vs CRL vs 2359.HK vs 3759.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
JOINN Laboratories (China) 6127.HK$3.70B+6%+17%-4%14.4×n/a
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Pharmaron Beijing 3759.HK$9.65B+48%+24%14%20.8×n/a
Labcorp LH$30.1B+44%+6%11%19.3×14.5%

How JOINN Laboratories (China) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JOINN Laboratories (China) against its 20 peers (data as of 18 Nov 2026)
Measure6127.HKPeer medianRank in peer set
1-month return-23.6%-5.3%2nd lowest of 21
6-month return+5.7%+1.1%10th highest of 21
Distance from 52-week high-38.4%-31.1%5th lowest of 21
Revenue growth (TTM)+16.7%+5.3%7th highest of 17
Operating margin-3.6%-0.7%7th lowest of 16
Forward P/E14.4×26.7×3rd cheapest of 10
ROIC minus cost of capital-12.4 pp-5.6 pp5th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%14.4×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%30.3×32.4%+7.1%
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%12.8×n/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a

Questions

Who are JOINN Laboratories (China)'s main competitors?
Named competitors: Charles River Laboratories (CRL), WuXi AppTec (2359.HK), Pharmaron Beijing (3759.HK), Labcorp Drug Development (LH). The cockpit's measured peer set (industry) also includes Tango Therapeutics (TNGX), Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Disc Medicine (IRON), CRISPR Therapeutics (CRSP), Beijing Tiantan Biological Products (600161.SS).
Is JOINN Laboratories (China) expensive compared with its peers?
On forward p/e it trades at 14.4× against a peer median of 26.7×, 3rd cheapest of 10 in its peer set.
How has JOINN Laboratories (China) stock performed?
Over six months to 18 Nov 2026 the shares returned +5.7% against +1.1% for the median peer; over one year +2.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.